HIV Management

Resource Center

Research Summaries

Research Summary

Research Summary

Is Long-Acting Injectable Cabotegravir–Rilpivirine Acceptable and Tolerable in Adolescents With HIV-1?

02/05/2016

Anthony Calabro, MA

A multicenter phase 1/2 trial evaluated the acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine over 48 weeks in adolescents with HIV-1, focusing on patient-reported pain,...

02/05/2016

prevention

In HIV, BMD May Be Improved With Bisphosphonates

09/15/2015

Individuals with HIV and low bone mineral density have a higher risk of osteoporosis and fractures. And although bisphosphonates are known to reduce the risk of fractures among adults, their safety and...

09/15/2015

HIV Management

New Discovery Could Thwart Spread of HIV

06/01/2015

Researchers have developed a new treatment method to prevent HIV cells from replicating and within the body.

06/01/2015

Conference Coverage

Conference Coverage

Long-Acting Cabotegravir PrEP Linked to Higher Coverage, Lower HIV Incidence

02/24/2015

Ashton L. Stahl

At CROI 2026 in Denver, CO, investigators reported real-world data from the OPERA cohort comparing cabotegravir long-acting injections with daily oral pre-exposure prophylaxis (PrEP), highlighting...

02/24/2015

Research Summary

Tenofovir Interruptions Linked to Hepatitis B Reactivation Risk in People with HIV in the United States

02/12/2015

Kate Young

A large US cohort study examined hepatitis B virus (HBV) monitoring practices and the risk of HBV reactivation and hepatitis flares during interruptions of tenofovir-containing antiretroviral therapy among...

02/12/2015

HIV Management Snapshot

Reviewed by Daniel Erias, MD & Jeffrey Kwong, DNP, MPH

For more infectious diseases content, visit the Disease State Hub

HIV is an infection caused by an enveloped retrovirus that weakens the immune system by reducing WBCs' ability to fight infections, bacterial infections, and certain cancers. Left untreated, HIV advances to acquired immunodeficiency syndrome.

For more emergency medicine content, visit the Resource Center

Primary care providers, infectious disease specialists, OB/GYN, pharmacists, dietitians, nutritionists, dentists, emergency, family, and internal medicine specialists.

For more influenza content, visit the Disease State Hub

Those with HIV may experience flu-like symptoms, including: Fever, sore throat, swollen lymph nodes, rash, muscle aches, night sweats, mouth ulcers, chills, and fatigue. However, some with an acute infection may not experience symptoms.

For more patient education content, visit the Resource Center

Despite high accuracy of diagnostic tests, there are no available options for detection immediately following infection. The type of test determines how quickly HIV is detected. Available tests: antibody, antigen/antibody, nucleic acid.

For more primary care content, visit the Resource Center

75% of infectious disease specialists act as primary care for patients with HIV.

For more patient-provider relationship content, visit the Resource Center

New HIV Diagnoses By Age, 2020

Age 13-24: 20%
Age 25-34: 37%
Age 35-44: 20%
Age 45-54: 13%
Age 55 & older: 10%

Research Summaries

Research Summary

Research Summary

Bictegravir–Lenacapavir Switch Maintains Viral Suppression in HIV-1, Phase 3 Trial Finds

06/09/2026

Ashton L. Stahl

A phase 3 trial found that switching from bictegravir–emtricitabine–tenofovir alafenamide to once-daily bictegravir–lenacapavir maintained viral suppression in adults with HIV-1.

06/09/2026

FDA Approval

FDA Approval

Doravirine/Islatravir (IDVYNSO) FDA Approval for Virologically Suppressed HIV-1 In Adults

05/13/2026

Anthony Calabro, MA

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

05/13/2026

Timeline Snapshot

Timeline Snapshot

Notable FDA Approvals in April

05/07/2026

April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

05/07/2026

Research Summary

Research Summary

Monthly Long-Acting Cabotegravir–Rilpivirine Reduces Regimen Failure in US Adults with HIV

03/10/2026

In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...

03/10/2026

Research summary

Research summary

Integrase Inhibitor Regimen Demonstrates Non-Inferiority, Fewer Adverse Events in Advanced HIV Disease

12/15/2025

Anthony Calabro, MA

In a large multicountry trial, researchers evaluated whether an integrase inhibitor–based regimen offers comparable or superior treatment outcomes to a boosted protease inhibitor regimen in adults with...

12/15/2025

June 2026

Current Issue

June 2026

Sources: